Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laurence Petty

Hospice and Palliative Medicine Plant City, FL Medical Doctor

NPI 1265655757 CMS profile 329975

8508 Alafia Hills Dr, Plant City, FL 33567

Open in the dashboard

General payments

$140,020

699 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laurence Petty of Plant City, FL is reported in the CMS Open Payments database as having received $140,020 across 699 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Hospice and Palliative Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,797 41
2024 General $33,917 129
2023 General $51,038 182
2022 General $14,800 150
2021 General $10,481 77
2020 General $8,097 54
2019 General $12,890 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laurence Petty
  • Hospice and Palliative Medicine median
  • Middle half of Hospice and Palliative Medicine
  • National median

In program year 2025, general payments to Laurence Petty were reported at $8,797. Among 378 Hospice and Palliative Medicine profiles paid that year, the median was $78 and the middle half received between $28 and $160.

Show as a table
Year Laurence Petty Hospice and Palliative Medicine median Middle half National median
2019 $12,890 $80 $22–$147 $163
2020 $8,097 $36 $18–$121 $114
2021 $10,481 $64 $23–$194 $132
2022 $14,800 $67 $22–$158 $149
2023 $51,038 $65 $25–$149 $160
2024 $33,917 $75 $25–$158 $164
2025 $8,797 $78 $28–$160 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $64,106 204 payments
  2. Otsuka America Pharmaceutical, Inc. $24,511 63 payments
  3. Lilly USA, LLC $21,907 62 payments
  4. Urovant Sciences Inc $11,899 42 payments
  5. ACADIA Pharmaceuticals Inc $5,581 61 payments
  6. Neurocrine Biosciences, Inc. $1,696 42 payments
  7. Avanir Pharmaceuticals, Inc. $1,298 38 payments
  8. AstraZeneca Pharmaceuticals LP $1,240 31 payments
  9. Sumitomo Pharma America, Inc. $1,237 8 payments
  10. Smith+Nephew, Inc. $1,091 24 payments
  11. Other $5,454 124 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $90,882 69 payments
  2. Food and Beverage $21,031 516 payments
  3. Travel and Lodging $18,290 105 payments
  4. Consulting Fee $9,722 7 payments
  5. Education $96 2 payments
Products named General payments · program years 2019–2025
  1. Nayzilam $60,740 121 payments
  2. REXULTI $24,658 63 payments
  3. TRULICITY $21,907 62 payments
  4. GEMTESA $13,069 49 payments
  5. NUPLAZID $5,320 50 payments
  6. Briviact $2,825 70 payments
  7. INGREZZA $1,447 40 payments
  8. NUEDEXTA $1,298 38 payments
  9. Epidiolex $1,095 26 payments
  10. LOKELMA $827 23 payments
  11. Other $8,185 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 249 drugs

Part D claims

19,787

Median for Internal Medicine: 777

Drug cost

$1,509,060

Median for Internal Medicine: $73,373

Branded share of claims

24.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 620 $207,938
Gemtesa Vibegron Brand 480 $128,115
Trulicity Dulaglutide Brand 92 $67,402
Aptiom Eslicarbazepine Acetate Brand 46 $52,033
Nuedexta Dextromethorphan Hbr/Quinidine Brand 67 $45,433
Xarelto Rivaroxaban Brand 101 $39,408
Divalproex Sodium Generic 484 $39,196
Oxycontin Oxycodone Hcl Brand 18 $33,930
Briviact Brivaracetam Brand 51 $31,302
Nuplazid Pimavanserin Tartrate Brand 12 $29,827

The 10 drugs with the highest cost, of 249 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$105,786

Medicare's payments for the services billed

Medicare patients

432

Average age 77

Services billed

1,099

251 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 73%
Arthritis 69%
Alzheimer's or dementia 64%
Diabetes 57%
Chronic kidney disease 49%
Ischemic heart disease 48%
Heart failure 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $17,026
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $159
$17,185 39 —
Nayzilam
  • UCB, Inc. $13,346
$13,346 27 —
GEMTESA
  • Sumitomo Pharma America, Inc. $992
$992 480 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $433
$433 53 —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $418
$418 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

699 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospice and Palliative Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record